FDA Grants First De Novo Authorization for Migraine Light-Filtering Lenses

The authorization marks a significant shift in how neurological light sensitivity is addressed, moving beyond the historical view of photophobia as a mere symptom toward recognizing it as a treatable condition. Avulux lenses function by blocking specific wavelengths at 480 nm and 590 nm, which are known to trigger or exacerbate migraine attacks, while allowing the remainder of the visible spectrum to pass through. The device is intended to be worn like standard eyewear and can be customized with or without vision correction.

Dr. Charles Posternack, co-founder and CEO of Avulux, noted that the designation provides patients and healthcare providers with a clear, validated option for managing the impact of light. The technology is designed to complement existing migraine therapies rather than replace them. Clinical support for the authorization includes randomized controlled trials and evidence gathered from over 50,000 users. With light sensitivity affecting nearly 90% of those living with migraine, the FDA's decision offers a new pathway for patients, pediatricians, and neurologists to address a frequently overlooked, yet highly disruptive, aspect of the disease.